Peripheral COMT-inhibition with Entacapon. Optimal therapy of Parkinson disease
Der Nervenarzt 70(6 Suppl): 1-8
1999
ISSN/ISBN: 0028-2804 PMID: 10399158 Document Number: 500790
Document emailed within 1 workday
Related Documents
Poewe, W. 2004: The role of COMT inhibition in the treatment of Parkinson's disease Neurology 62(1 Suppl 1): S31-S38Rabasseda, X. 1999: Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies Drugs of Today 35(9): 701-717
Marshall, M. 1982: Thrombocyte function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 1. Pathogenesis, prevention, therapy Fortschritte der Medizin 100(14): 650-655
Nutt, J.G. 1996: Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA Advances in Neurology 69: 493-496
Cernibori 1970: Electrophysiological effect of Levodopa on the phenomena of spinal inhibition and facilitation in Parkinson's disease Rivista di Neurologia 40(5): 303-309
Scigliano, G.; Musicco, M.; Soliveri, P.; Girotti, F.; Giovannini, P.; Fetoni, V.; Caraceni, T. 1996: Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy Advances in Neurology 69: 305-309
Banach, T.; Zurowski, D.; Gil, K.; Krygowska-Wajs, A.; Marszałek, A.; Thor, P.J. 2006: Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson's disease Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society 57(2): 291-300
Chovancová, Z.; Kanovský, P.; Nestrasil, I.; Dufek, J.; Nevrlý, M.; Otruba, P. 2008: Peripheral nerve injury and the degree of motor involvement in Parkinson's disease: a correlation study Casopis Lekaru Ceskych 147(4): 211-214
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Roth, J.; Růzicka, E.; Kanovský, P. 2000: Advance in therapy Parkinson's disease Vnitrni Lekarstvi 46(11): 811-816
Bhat, V.; Weiner, W.J. 2005: Parkinson's disease. Diagnosis and the initiation of therapy Minerva Medica 96(3): 145-154
Möller, J.C.; Sautter, J.; Kupsch, A. 1996: Potential of neurotrophic factors in therapy of Parkinson's disease Journal of Neural Transmission. Supplementum 48: 103-112
Chase, T.N.; Baronti, F.; Fabbrini, G.; Heuser, I.J.; Juncos, J.L.; Mouradian, M.M. 1989: Rationale for continuous dopaminomimetic therapy of Parkinson's disease Neurology 39(11 Suppl 2: 7
Pacchetti, C.; Aglieri, R.; Mancini, F.; Martignoni, E.; Nappi, G. 1998: Active music therapy and Parkinson's disease: methods Functional Neurology 13(1): 57-67
Mera, S.L. 1996: Parkinson's disease: prospects for prevention and improved therapy British Journal of Biomedical Science 53(3): 177-178
Slattery, J. 2000: Placebo surgery in trials of therapy for Parkinson's disease New England Journal of Medicine 342(5): 354; Author Reply 355